SCHEMBL5819782

SCHEMBL5819782

NNC(=O)C(N)CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.42
LTA4H P09960 2/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
GABRR1 P24046 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KDM5C P41229 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
LMNA P02545 1/20 0.37
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GSR P00390 1/20 0.36
CYP1A2 P05177 1/20 0.36
GRIK1 P39086 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27468494 1.00 HIF1A (0.42) HIF1ALTA4HSLC22A6GABRR1KDM4E
SCHEMBL1372611 1.00 HIF1A (0.42) HIF1ALTA4HSLC22A6GABRR1KDM4E
SCHEMBL11414379 0.80 SMN1; SMN2 (0.52) HIF1ASLC22A6GABRR1KDM4EKDM5C
SCHEMBL28509229 0.80 HIF1A (0.42) HIF1ALMNACYP1A2CTSD
SCHEMBL2113218 0.80 HIF1A (0.42) HIF1AKDM4EKDM5CPHF8KDM2A
SCHEMBL9921298 0.80 HIF1A (0.42) HIF1ALMNACYP1A2CTSD
SCHEMBL6923760 0.80 HIF1A (0.42) HIF1AKDM4EKDM5CPHF8KDM2A
SCHEMBL1419558 0.80 FOLH1 (0.41) LTA4HSLC22A6GABRR1LMNAS1PR1
SCHEMBL16295014 0.78 S1PR1 (0.42) LTA4HSLC22A6GABRR1S1PR1S1PR3
SCHEMBL6958934 0.78 LTA4H (0.37) LTA4HSLC22A6GABRR1LMNAS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019198923-A1 MICROSTRUCTURE FOR TRANSCUTANEOUS AND INTRACUTANEOUS DRUG DELIVERY OF CYCLOSPORIN A (CSA) 가천대학교 산학협력단 2019-10-17 WO claimed
CN-112770734-B Inhibition method 堪培拉大学 2024-08-20 CN disclosed
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-02-09 US disclosed
US-11123439-B2 Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-09-21 US disclosed
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-07-27 US disclosed
CN-112770734-A Suppression method 堪培拉大学 2021-05-07 CN disclosed
US-20200360531-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2020-11-19 US disclosed
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-08-18 US disclosed
US-20200138970-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-07 US disclosed
WO-2019198923-A1 MICROSTRUCTURE FOR TRANSCUTANEOUS AND INTRACUTANEOUS DRUG DELIVERY OF CYCLOSPORIN A (CSA) 가천대학교 산학협력단 2019-10-17 WO disclosed
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-17 US disclosed
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES Bayer Pharma AG (DE) 2018-07-05 US disclosed
US-20180169256-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-06-21 US disclosed
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 US disclosed
WO-2017060322-A2 PTEFB-INHIBITOR-ADC BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-04-13 WO disclosed
WO-2006115293-A1 NOVEL BLOCK COPOLYMER USED FOR PREPARING pH-RESPONSIVE POLYMER MICELLE, AND METHOD FOR PRODUCING SAME THE UNIVERSITY OF TOKYO (JP) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies KIF23, KIF2C, KIF18A HIF1A 3566/4885LTA4H 4447/4885SLC22A6 2042/4885
US-11123439-B2 Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups KIFC1, KIF2C, KIF5B HIF1A 4704/4885LTA4H 4564/4885SLC22A6 1051/4885
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) KIF5B, KIF23, KIF2C HIF1A 2361/4885LTA4H 4489/4885SLC22A6 2732/4885
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies KIF23, KIF5B, KIF2C HIF1A 3507/4885LTA4H 4004/4885SLC22A6 2914/4885
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES KIF23, KIF5B, KIF2C HIF1A 3390/4885LTA4H 3507/4885SLC22A6 2696/4885
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES TNFSF11, TNFRSF9, CD40 HIF1A 2125/4885LTA4H 4159/4885SLC22A6 3364/4885
US-20200138970-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTIB7H3-ANTIBODIES KIF23, KIF5B, KIF2C HIF1A 3507/4885LTA4H 4004/4885SLC22A6 2914/4885
US-20180169256-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS KIFC1, KIF2C, KIF5B HIF1A 4704/4885LTA4H 4564/4885SLC22A6 1051/4885
US-20200360531-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS NAMPT, B3GNT2, NQO1 HIF1A 3068/4885LTA4H 2006/4885SLC22A6 261/4885
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS KIFC1, KIF2C, KIF5B HIF1A 4704/4885LTA4H 4564/4885SLC22A6 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.